To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

The global cell and gene therapy market size is valued at USD 27.02 billion in 2025 and is predicted to hit around USD 232.22 ...

(NewsNation) — Doctors used personal gene therapy to treat an infant with a deadly genetic disease in a medical first. KJ Muldoon was born in August of 2024, and DNA sequencing revealed he had ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...